Physician profile
Thomas W Bond
NPI 1003891219
$3,097.13
in general payments reported to CMS, 2019-2025
30 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $119 · 2021: $240 · 2022: $557 · 2023: $693 · 2024: $674 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,826.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $660.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $381.37 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $323.59 | 2022-2024 | |
| Glaxosmithkline, LLC. | $248.83 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Pfizer INC. | $232.30 | 2019-2025 | |
| Abbvie INC. | $214.73 | 2021-2025 | Qulipta, Ubrelvy |
| Exact Sciences Corporation | $177.03 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $102.18 | 2023-2025 | Auvelity, Symbravo |
| Lilly USA, LLC | $99.45 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $90.39 | 2019-2024 | Evenity |
| Janssen Pharmaceuticals, INC | $66.05 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.46 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.69 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.27 | 2019-2021 | |
| Amarin Pharma, INC. | $43.75 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $43.37 | 2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $29.17 | 2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $27.56 | 2022 | |
| Astellas Pharma US INC | $25.96 | 2021-2024 | Veozah |
| Lexicon Pharmaceuticals, INC. | $21.22 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.22 | 2024 | Caplyta |
| Corcept Therapeutics | $18.56 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $16.91 | 2024 | Voquezna |
| Corium, LLC | $16.60 | 2024 | Azstarys |
| Xeris Pharmaceuticals, INC. | $16.56 | 2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $15.07 | 2022 | |
| Genentech USA, INC. | $15.00 | 2020 | |
| Paratek Pharmaceuticals, INC. | $13.85 | 2024 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $13.04 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.